GNLX insider transaction filings
GENELUX Corp — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-02. Screen GNLX transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 7 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 7 legs across 7 filings by 4 insiders — 70,732 shares, $194,320 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 0.
- Largest priced transaction: sale of 34,463 shares @ $2.67 ($91,899) by Zindrick Thomas, filed 2026-09-02.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| Zindrick Thomas — President and CEO | 2 | — | 2 legs · 37,486 sh · $100,804 | — |
| Smither John W — Director | 1 | — | 1 leg · 12,000 sh · $34,898 | — |
| Cappello Joseph — Chief Technical Officer | 2 | — | 2 legs · 10,910 sh · $30,037 | — |
| Yu Yong — Chief Scientific Officer | 2 | — | 2 legs · 10,336 sh · $28,580 | — |
Recent Form 4 filings — GENELUX Corp
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-02 | 4 | Yu Yong — Chief Scientific Officer | Sale (S): 9,683 @ $2.75 | EDGAR |
| 2026-09-02 | 4 | Zindrick Thomas — President and CEO | Sale (S): 34,463 @ $2.67 | EDGAR |
| 2026-09-02 | 4 | Cappello Joseph — Chief Technical Officer | Sale (S): 10,257 @ $2.74 | EDGAR |
| 2026-08-04 | 4 | Zindrick Thomas — President and CEO | Sale (S): 3,023 @ $2.95 | EDGAR |
| 2026-08-04 | 4 | Cappello Joseph — Chief Technical Officer | Sale (S): 653 @ $2.95 | EDGAR |
| 2026-08-04 | 4 | Yu Yong — Chief Scientific Officer | Sale (S): 653 @ $2.94 | EDGAR |
| 2026-07-02 | 4 | Smither John W — Director | Sale (S): 12,000 @ $2.91 | EDGAR |
| 2026-06-18 | 4 | Pulisic Matthew — Chief Financial Officer | Grant/award (A): 278,906 @ $0 | EDGAR |
| 2026-06-18 | 4 | Groen Eric — General Counsel | Grant/award (A): 233,957 @ $0 | EDGAR |
| 2026-06-18 | 4 | Cappello Joseph — Chief Technical Officer | Grant/award (A): 174,841 @ $0 | EDGAR |
| 2026-06-18 | 4 | Tyree James L — Director | Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Zindrick Thomas — President and CEO | Grant/award (A): 730,601 @ $0 | EDGAR |
| 2026-06-18 | 4 | Thomas John — Director | Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Mirabelli Mary — Director | Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | Yu Yong — Chief Scientific Officer | Grant/award (A): 119,318 @ $0 | EDGAR |
| 2026-06-18 | 4 | Smither John W — Director | Grant/award (A): 28,409 @ $0 · Grant/award (A): 31,566 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Smalling Ralph — Head of Regulatory | Sale (S): 192 @ $2.93 | EDGAR |
| 2026-06-02 | 4 | Thomas John — Director | Sale (S): 10,000 @ $2.98 | EDGAR |
| 2026-05-12 | 4 | Cappello Joseph — Chief Technical Officer | Sale (S): 605 @ $2.97 | EDGAR |
| 2026-05-12 | 4 | Yu Yong — Chief Scientific Officer | Sale (S): 605 @ $2.97 | EDGAR |
| 2026-05-12 | 4 | Zindrick Thomas — President and CEO | Sale (S): 2,798 @ $2.94 | EDGAR |
| 2026-05-12 | 4 | Smalling Ralph — Head of Regulatory | Sale (S): 270 @ $2.98 | EDGAR |
| 2026-03-26 | 4 | Smalling Ralph — Head of Regulatory | Sale (S): 345 @ $2.42 · Sale (S): 240 @ $2.51 | EDGAR |
| 2026-03-26 | 4 | Cappello Joseph — Chief Technical Officer | Sale (S): 906 @ $2.42 | EDGAR |
| 2026-03-26 | 4 | Yu Yong — SVP, Clinical Development | Sale (S): 906 @ $2.42 | EDGAR |
| 2026-03-26 | 4 | Zindrick Thomas — President and CEO | Sale (S): 3,582 @ $2.42 | EDGAR |
| 2026-03-03 | 4 | Thomas John — Director | Sale (S): 10,000 @ $2.90 | EDGAR |
| 2026-01-07 | 4 | Litten Jason — Chief Medical Officer | Grant/award (A): 275,000 (derivative) @ $0 | EDGAR |
| 2025-12-11 | 4 | Zindrick Thomas — President and CEO | Sale (S): 12,673 @ $3.33 · Sale (S): 4,509 @ $5.37 | EDGAR |
| 2025-12-11 | 4 | Yu Yong — SVP, Clinical Development | Sale (S): 3,219 @ $3.36 · Sale (S): 973 @ $5.37 | EDGAR |
| 2025-12-11 | 4 | Cappello Joseph — Chief Technical Officer | Sale (S): 1,270 @ $3.33 · Sale (S): 1,463 @ $3.36 · Sale (S): 973 @ $5.37 | EDGAR |
| 2025-12-09 | 4 | Smalling Ralph — Head of Regulatory | Sale (S): 1,244 @ $3.36 · Sale (S): 580 @ $3.36 · Sale (S): 343 @ $5.37 · Sale (S): 165 @ $4.69 | EDGAR |
| 2025-12-02 | 4 | Thomas John — Director | Sale (S): 10,000 @ $5.00 | EDGAR |
| 2025-09-03 | 4 | Zindrick Thomas — President and CEO, Director | Disposition to issuer (D): 925,000 (derivative) · Grant/award (A): 925,000 (derivative) · Disposition to issuer (D): 157,372 (derivative) · Grant/award (A): 157,372 (derivative) · Disposition to issuer (D): 23,568 (derivative) · Grant/award (A): 23,568 (derivative) · +2 more | EDGAR |
| 2025-09-03 | 4 | Yu Yong — SVP, Clinical Development | Disposition to issuer (D): 207,652 (derivative) · Grant/award (A): 207,652 (derivative) · Disposition to issuer (D): 65,000 (derivative) · Grant/award (A): 65,000 (derivative) | EDGAR |
| 2025-09-03 | 4 | Smalling Ralph — Head of Regulatory | Grant/award (A): 10,000 @ $0 · Disposition to issuer (D): 8,333 (derivative) · Grant/award (A): 8,333 (derivative) | EDGAR |
| 2025-09-03 | 4 | Cappello Joseph — Chief Technical Officer | Disposition to issuer (D): 16,666 (derivative) · Grant/award (A): 16,666 (derivative) · Disposition to issuer (D): 80,000 (derivative) · Grant/award (A): 80,000 (derivative) · Disposition to issuer (D): 13,333 (derivative) · Grant/award (A): 13,333 (derivative) · +2 more | EDGAR |
| 2025-08-29 | 4 | Tyree James L — Director | Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Smither John W — Director | Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Mirabelli Mary — Director | Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Thomas John — Director | Grant/award (A): 22,283 @ $0 · Grant/award (A): 28,576 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Zindrick Thomas — President and CEO | Grant/award (A): 361,200 @ $0 · Grant/award (A): 478,800 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Yu Yong — SVP, Clinical Development | Grant/award (A): 101,480 @ $0 · Grant/award (A): 134,520 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Smalling Ralph — Head of Regulatory | Grant/award (A): 26,230 @ $0 · Grant/award (A): 34,770 (derivative) @ $0 | EDGAR |
| 2025-08-29 | 4 | Cappello Joseph — Chief Technical Officer | Grant/award (A): 107,500 @ $0 · Grant/award (A): 142,500 (derivative) @ $0 | EDGAR |
| 2025-07-02 | 4 | Groen Eric — General Counsel & Secretary | Grant/award (A): 270,000 (derivative) @ $0 | EDGAR |
| 2025-06-24 | 4 | Thomas John — Director | Gift (G): 25,000 @ $0 | EDGAR |
| 2025-05-13 | 4 | Yu Yong — VP, Clinical Trial Operations | Sale (S): 5,579 @ $2.92 | EDGAR |
| 2025-05-13 | 4 | Cappello Joseph — VP, Pharmaceutical Development | Sale (S): 4,737 @ $2.92 | EDGAR |
| 2025-05-13 | 4 | Smalling Ralph — Head of Regulatory | Sale (S): 1,259 @ $2.92 | EDGAR |
Recent 8-K events — GENELUX Corp
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2026-03-19 | 8-K | 1.01 — Entry into a Material Definitive Agreement 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-02 | 8-K | 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-08 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-05 | 8-K | 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-01-02 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-09-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders | EDGAR |
| 2025-03-25 | 8-K | 2.02 — Results of Operations and Financial Condition 7.01 — Regulation FD Disclosure 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-03-25 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-02-03 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=GNLX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →